ConductScience.org, home

Paper31258882

Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease.

Luinstra M and 9 others. Ther Adv Chronic Dis, 2019. Cited by 24 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease. Papers, record 31258882. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31258882

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease.
PubMed
Journal
Ther Adv Chronic Dis
PubMed
Year
2019
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
24
iCite
Relative citation ratio, by iCite
1.54
iCite
Revised in PubMed
2022-04-09
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Luinstra MMarianne
2Rutgers WWijnand
3van Laar TTeus
4Grasmeijer FFlorishttps://orcid.org/0000-0003-0897-5673
5Begeman AAnja
6Isufi VValmira
7Steenhuis LLuc
8Hagedoorn PPaul
9de Boer AAnne
10Frijlink HWHenderik W

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References26

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
111,948,753Pathophysiology of Parkinson's disease: from clinical neurology to basic neuroscience and back.Mov Disord2002https://conductscience.org/library/papers/11948753PubMed
216,055,882Standardisation of spirometry.Eur Respir J2005https://conductscience.org/library/papers/16055882PubMed
316,113,455The lungs as a portal of entry for systemic drug delivery.Proc Am Thorac Soc2004https://conductscience.org/library/papers/16113455PubMed
416,368,444A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.Clin Ther2005https://conductscience.org/library/papers/16368444PubMed
516,485,914Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.Clin Pharmacokinet2006https://conductscience.org/library/papers/16485914PubMed
617,630,819Medical management of levodopa-associated motor complications in patients with Parkinson's disease.CNS Drugs2007https://conductscience.org/library/papers/17630819PubMed
717,956,200Apomorphine therapy in Parkinson's disease: a review.Expert Opin Pharmacother2007https://conductscience.org/library/papers/17956200PubMed
821,838,677Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease.CNS Neurol Disord Drug Targets2011https://conductscience.org/library/papers/21838677PubMed
922,632,782Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease.J Neurol Sci2012https://conductscience.org/library/papers/22632782PubMed
1023,287,001Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.Parkinsonism Relat Disord2013https://conductscience.org/library/papers/23287001PubMed
1123,480,198Inhaled biopharmaceutical drug development: nonclinical considerations and case studies.Inhal Toxicol2013https://conductscience.org/library/papers/23480198PubMed
1223,487,540Review: management of Parkinson's disease.Neuropsychiatr Dis Treat2013https://conductscience.org/library/papers/23487540PubMed
1325,449,210Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.Mov Disord2015https://conductscience.org/library/papers/25449210PubMed
1425,615,881The Cyclops for pulmonary delivery of aminoglycosides; a new member of the Twincer™ family.Eur J Pharm Biopharm2015https://conductscience.org/library/papers/25615881PubMed
1526,173,114Can Patients with Parkinson's Disease Use Dry Powder Inhalers during Off Periods?PLoS One2015https://conductscience.org/library/papers/26173114PubMed
1626,453,913A levodopa dry powder inhaler for the treatment of Parkinson's disease patients in off periods.Eur J Pharm Biopharm2015https://conductscience.org/library/papers/26453913PubMed
1726,474,316MDS clinical diagnostic criteria for Parkinson's disease.Mov Disord2015https://conductscience.org/library/papers/26474316PubMed
1826,959,239Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients.PLoS One2016https://conductscience.org/library/papers/26959239PubMed
1927,733,560Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's disease.Sci Transl Med2016https://conductscience.org/library/papers/27733560PubMed
202,775,615The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa.Br J Clin Pharmacol1989https://conductscience.org/library/papers/2775615PubMed

See all 26 references

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.

PMIDTitleJournalYearIn PapersSource
42,646,580Clinical Use Patterns and Patient-Reported Experience with Inhaled Levodopa in Routine Practice: A Two-Center Study.Med Sci (Basel)2026https://conductscience.org/library/papers/42646580PubMed
42,181,371Controlled Maxillofacial Administration of Levodopa in a Patient With Parkinson's Disease: A First-in-Human 24-Hour Follow-Up Study.Cureus2026https://conductscience.org/library/papers/42181371PubMed
42,162,439Recent Developments in the Drug Treatment of Parkinson's Disease.Drugs2026https://conductscience.org/library/papers/42162439PubMed
41,012,486An In Vitro-In Vivo Comparison of Two Levodopa Dry Powder Products for Inhalation: A Randomized Trial Comparing Inbrija and Levodopa Cyclops.Pharmaceutics2025https://conductscience.org/library/papers/41012486PubMed
40,775,197Opportunities for and Challenges of Pulmonary Drug Delivery in the Management of Acute Exacerbations of CNS Disorders.CNS Drugs2025https://conductscience.org/library/papers/40775197PubMed
40,464,628The Treatment of Older Patients with Parkinson's Disease.Dtsch Arztebl Int2025https://conductscience.org/library/papers/40464628PubMed
40,284,461Optimization, In Vitro, and In Silico Characterization of Theophylline Inhalable Powder Using Raffinose-Amino Acid Combination as Fine Co-Spray-Dried Carriers.Pharmaceutics2025https://conductscience.org/library/papers/40284461PubMed
39,945,036Stabilized Extracellular Vesicle Formulations for Inhalable Dry Powder Development.Small2026https://conductscience.org/library/papers/39945036PubMed
39,483,816Therapeutic effect of an inhaled levodopa dry powder formulation on off episodes in patients with Parkinson's disease.Ther Adv Neurol Disord2024https://conductscience.org/library/papers/39483816PubMed
38,034,171The Administration of Levodopa in a Patient With Parkinson's Disease Using a Novel Maxillofacial Route: A First-in-Human Report.Cureus2023https://conductscience.org/library/papers/38034171PubMed
37,182,902Drugs to the Rescue: Comparison of On-Demand Therapies for OFF Symptoms in Parkinson's Disease.J Parkinsons Dis2023https://conductscience.org/library/papers/37182902PubMed
36,559,312Development and Pharmacokinetics of a Novel Acetylsalicylic Acid Dry Powder for Pulmonary Administration.Pharmaceutics2022https://conductscience.org/library/papers/36559312PubMed
35,775,493Non-Oral Drug Delivery in Parkinson's Disease: Current Applications and Future.Turk J Pharm Sci2022https://conductscience.org/library/papers/35775493PubMed
35,747,892Inhaled Levodopa (CVT-301) for the Treatment of Parkinson Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Neurol Clin Pract2022https://conductscience.org/library/papers/35747892PubMed
35,026,316The future of dry powder inhaled therapy: Promising or discouraging for systemic disorders?Int J Pharm2022https://conductscience.org/library/papers/35026316PubMed
34,575,603Optimizing Spray-Dried Porous Particles for High Dose Delivery with a Portable Dry Powder Inhaler.Pharmaceutics2021https://conductscience.org/library/papers/34575603PubMed
33,117,256Intrinsic Auricular Muscle Zone Stimulation Improves Walking Parameters of Parkinson's Patients Faster Than Levodopa in the Motion Capture Analysis: A Pilot Study.Front Neurol2020https://conductscience.org/library/papers/33117256PubMed

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
COMT1,312PubTator's text mininghttps://conductscience.org/library/genes/1312NCBI Gene
MAOB4,129PubTator's text mininghttps://conductscience.org/library/genes/4129NCBI Gene

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31258882

GET https://conductscience.org/api/papers/v1/31258882/references?page=2